Physicians’ Perspectives on Their Training for and Role Within Pennsylvania’s Medical Cannabis Program

References

1. 1.↵
   MPP. Medical marijuana patient numbers. Mpp. Published 2021. Accessed May 11, 2021. Available from: https://www.mpp.org/issues/medical-marijuana/state-by-state-medical-marijuana-laws/medical-marijuana-patient-numbers/.
2. 2.↵
   State Medical Marijuana Laws. National Conference of State Legislatures. Published 2021. Accessed April 2, 2021. Available from: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
3. 3.↵
   1. Temple LM,
   2. Lampert SL,
   3. Ewigman B

   . Barriers to achieving optimal success with medical cannabis: opportunities for quality improvement. J Altern Complement Med 2019;25:5–7.

   OpenUrl
4. 4.↵
   1. Zylla D,
   2. Steele G,
   3. Eklund J,
   4. Mettner J,
   5. Arneson T

   . Oncology clinicians and the Minnesota Medical Cannabis Program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs. Cannabis Cannabinoid Res 2018;3:195–202.

   OpenUrl
5. 5.↵
   1. Worster B,
   2. Ashare RL,
   3. Hajjar E,
   4. Garber G,
   5. Smith K,
   6. Kelly EL

   . Clinician attitudes, training, and beliefs about cannabis: an interprofessional assessment. Cannabis Cannabinoid Res 2021;X:1–10.
6. 6.↵
   1. Ananth P,
   2. Ma C,
   3. Al-Sayegh H,
   4. et al

   . Provider perspectives on use of medical marijuana in children with cancer. Pediatrics 2018;141:1–10.

   OpenUrlPubMed
7. 7.↵
   1. Rubin R

   . Medical Marijuana is legal in most states, but physicians have little evidence to guide them. JAMA 2017;317:1611–3.

   OpenUrlPubMed
8. 8.↵
   1. Haug NA,
   2. Kieschnick D,
   3. Sottile JE,
   4. Babson KA,
   5. Vandrey R,
   6. Bonn-Miller MO

   . Training and practices of cannabis dispensary staff. Cannabis Cannabinoid Res 2016;1:244–51.

   OpenUrl
9. 9.↵
   1. Reed MK,
   2. Kelly EL,
   3. Wagner B,
   4. Hajjar E,
   5. Garber G,
   6. Worster B

   . A failure to guide: patient experiences within a state-run cannabis program in Pennsylvania, United States. Subst Use Misuse 2022;57:516–21.

   OpenUrl
10. 10.↵
    1. Reece S,
    2. Holle L,
    3. Mukherjee K

    . Survey of pharmacists’ knowledge of Connecticut’s medical cannabis program. Cannabis Cannabinoid Res 2021;6:66–73.

    OpenUrl
11. 11.↵
    1. Gardiner KM,
    2. Singleton JA,
    3. Sheridan J,
    4. Kyle GJ,
    5. Nissen LM

    . Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis—A systematic review. PLoS One 2019;14:e0216556–13.

    OpenUrlPubMed
12. 12.↵
    1. Christensen VA,
    2. Nugent SM,
    3. Ayers CK,
    4. Morasco BJ,
    5. Kansagara D

    . A qualitative study of VHA clinicians’ knowledge and perspectives on cannabis for medical purposes. Fam Pract 2021;38:479–83.

    OpenUrl
13. 13.↵
    1. Hsieh HF,
    2. Shannon SE

    . Three approaches to qualitative content analysis. Qual Health Res 2005;15:1277–88.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Kondrad E,
    2. Reid A

    . Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med 2013;26:52–60.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Saeed SA,
    2. Masters RMR

    . Disparities in health care and the digital divide. Curr Psychiatry Rep 2021;23:1–6.

    OpenUrl
16. 16.↵
    1. Chagpar AB

    . Sociodemographic factors affecting telemedicine access: A population-based analysis. Surg (United States) 2022;171:793–8.

    OpenUrl
17. 17.↵
    1. Merlin JS,
    2. Althouse A,
    3. Feldman R,
    4. et al

    . Analysis of state cannabis laws and dispensary staff recommendations to adults purchasing medical cannabis. JAMA Netw Open 2021;4:e2124511–11.

    OpenUrl
18. 18.↵
    1. Carliner H,
    2. Brown QL,
    3. Sarvet AL,
    4. Hasin DS

    . Cannabis use, attitudes, and legal status in the U.S.: A review. Prev Med 2017;104:13–23.

    OpenUrlPubMed